Global pharma major Lupin Limited has announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. The product is indicated for the chronic management of patients with Urea Cycle Disorders (UCDs) who cannot be adequately managed through dietary protein restriction and/or amino acid supplementation alone.
This launch marks another significant milestone for Lupin as it continues to expand its specialty and complex generic portfolio in the U.S. market. Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL, offers an important therapeutic option for patients living with UCDs—a group of rare genetic disorders that affect the body’s ability to remove ammonia from the bloodstream.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence in over 100 markets worldwide. The company’s portfolio includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs).
Lupin is recognized for its expertise across multiple therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. The company operates 15 state-of-the-art manufacturing facilities and 7 cutting-edge research centers across the globe, supported by a team of more than 24,000 professionals.
Beyond pharmaceuticals, Lupin continues to strengthen its focus on holistic healthcare solutions through its subsidiaries—Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions—aimed at improving patient outcomes and advancing access to high-quality healthcare.
